期刊名称：FUTURE ONCOLOGY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
The next few decades will see dramatic changes within the field of oncology. Whilst the burden of disease is set to increase, the available armamentarium to the oncologist will be greater, more robust and offer the potential to focus on individual needs. Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community.
The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues, that confront us in a new era of cancer care. The journal includes news and views, literature awareness regarding new biomarkers, concise commentary and analysis, reports from the conference circuit and full review articles.
Topics addressed include:
- Biological processes involved in cancer and how new understanding will impact treatment
- Clinical implications and applications for new biomarkers
- Impact of molecular genetics on prevention, screening, diagnosis and treatment
- Integration of diagnostic and therapeutic approaches
- Profiles of new anticancer agents
- Selective and 'personalized' approaches
- Screening programs and methodology
Indexing
- MEDLINE/Index Medicus
- EMBASE/Excerpta Medica
- Chemical Abstracts
- Scopus
Instructions to Authors
We accept unsolicited manuscripts for publication in Future Medicine journals. All review articles published in the journals are subject to rigorous peer-review by independent experts in the field. If you are interested in submitting an article, please contact the Commissioning Editor of the relevant journal with a brief proposal and article outline in the first instance. We also have an active commissioning program whereby the Commissioning Editor, under the advice of the Editorial Advisory Board, solicits articles for publication by Future Medicine.
The following guidelines (in PDF format) are provided to assist authors in the preparation of their manuscript.
Author Guidelines
For authors preparing Drug Evaluations or Clinical Trial Commentaries, please contact Laura Dormer for article-specific guidelines.
References
The Future Medicine EndNote style for references is available here (compatible with Mac EndNote 9).
The Future Medicine Reference Manager Style is available here.
Copyright
As the author of your manuscript, you are responsible for obtaining permissions to use material owned by others. Since the permission-seeking process can be time-consuming, it is wise to request permission as soon as possible. A template permission letter is available upon request by contacting the Commissioning Editor of the relevant journal. Please send us photocopies of letters or forms granting you permission for the use of copyrighted material so that we can see that any special requirements with regard to wording and placement of credits are fulfilled. Please keep the originals for your files. Future Medicine is a signatory to the STM Permissions Guidelines produced by the International Association of Scientific, Medical and Technical Publishers. As such, permission will be, or in the case of an express permission requirement should be, granted free of charge by other signatory organizations to use up to three figures (including tables) from a journal article or book chapter and to use single text extracts of less than 400 words from a journal article or book chapter (for full details, please refer to the Author Guidelines). Authors should note that although permission may be granted without charge, authors must ensure that appropriate permission has nevertheless been obtained.
Online submission
At Future Medicine we believe in quality of author service. We therefore do not offer a formal online submission option – we prefer to manage our relationship with authors on a personal level from the outset. Authors should simply e-mail their manuscript to the relevant member of the editorial team (see Contact Us). They will receive confirmation of receipt from a member of the editorial team and will be able to discuss the status of their article, by telephone, fax or e-mail. We aim to respond to any query (editorial or otherwise) within 24 hours.
Please submit manuscripts in Microsoft Word 2000 format via e-mail to the Commissioning Editor of the relevant journal. Figures should be submitted as Microsoft PowerPoint, Adobe Illustrator or Photoshop (*.eps). Graphs and charts can also be submitted as Microsoft Excel.
If you are uncertain who to contact or have any queries about your contribution, please contact:
Elisa Manzotti, Editorial Director, Future Medicine Ltd, Unitec House, 2 Albert Place, London, N3 1QB, UK
Tel.: +44 (0)20 8371 6090; Fax: +44 (0)20 8343 2313
Editorial policy
Future Medicine titles endorse the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, issued by the International Committee for Medical Journal Editors, and Code of Conduct for Editors of Biomedical Journals, produced by the Committee on Publication Ethics. Our full Editorial Policy can be found in the Author Guidelines.
Manuscript submission & processing
Future Medicine titles publish solicited and unsolicited articles. Receipt of all manuscripts will be acknowledged within 1 week and authors will be notified as to whether the article is to progress to external review. Initial screening of articles by internal editorial staff will assess the topicality and importance of the subject, the clarity of presentation, and relevance to the audience of the journal in question.
If you are interested in submitting an article, or have any queries regarding article submission, please contact the Managing Commissioning Editor for the journal (see Contact Us). For new article proposals, the Managing Commissioning Editor will require a brief article outline and working title in the first instance. We also have an active commissioning program whereby the Commissioning Editor, under guidance from the Editorial Advisory Panel, solicits articles directly for publication.
External peer review
Through a rigorous peer review process, our titles aim to ensure that articles are unbiased, scientifically accurate and clinically relevant. All articles are peer reviewed by three or more members of the International Advisory Board or other specialists selected on the basis of experience and expertise. Review is performed on a double-blind basis – the identities of peer reviewers and authors are kept confidential. Peer reviewers must disclose potential conflicts of interests that may affect their ability to provide an unbiased appraisal (see Conflict of Interest Policy below). Peer reviewers complete a referee report form, to provide general comments to the editor and both general and specific comments to the author(s).
Where an author believes that an editor has made an error in declining a paper, they may submit an appeal. The appeal letter should clearly state the reasons why the author(s) considers the decision to be incorrect and provide detailed, specific responses to any comments relating to the rejection of the article. Further advice from members of the journal’s Editorial Advisory Panel external experts will be sought regarding eligibility for re-review.
Revision
Most manuscripts require some degree of revision prior to acceptance. Authors should provide two copies of the revised manuscript – one of which should be highlighted to show where changes have been made. Detailed responses to reviewers’ comments, in a covering letter/email, are also required. Manuscripts may be accepted at this point or may be subject to further peer review. The final decision on acceptability for publication lies with the journal editor.
Post-acceptance
Accepted manuscripts are edited by the in-house editorial team. Authors will receive proofs of their article for approval and sign-off and will be asked to sign a transfer of copyright agreement, except in circumstances where the author is ineligible to do so (e.g. government employees in certain countries).
Author disclosure & conflict of interest policy
Authors must state explicitly whether potential conflicts do or do not exist (e.g. personal or financial relationships that could influence their actions) and any such potential conflict of interest (including sources of funding) should be summarized in a separate section of the published article. Authors must disclose whether they have received writing assistance and identify the sources of funding for such assistance. Authors declaring no conflict of interest are required to publish a statement to that effect within the article.
Authors must certify that all affiliations with or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in their manuscript have been disclosed. Please note that examples of financial involvement include: employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending and royalties. This is list is not exclusive of other forms of financial involvement. Details of relevant conflicts of interests (or the lack of) must be declared in the ‘Disclosure’ section of the manuscript for all listed authors.
External peer reviewers must disclose any conflicts of interest that could bias their opinions of the manuscript, and they should disqualify themselves from reviewing specific manuscripts if they believe it appropriate. Should any such conflict of interest be declared, the journal editor will judge whether the reviewer’s comments should be recognized or will interpret the reviewer’s comments in the context of any such declaration.
Ethical conduct of research
Where articles include publication of original data relating to human or animal experimental investigations, appropriate institutional review board approval is required and should be described within the article. For those investigators who do not have formal ethics review committees, the principles outlined in the Declaration of Helsinki should be followed. For investigations involving human subjects, authors should explain how informed consent was obtained from the participants involved.
Patients’ rights to privacy
Patients have a right to privacy that should not be infringed without informed consent. Identifying information should not be included unless the information is essential for scientific purposes and the patient (or parent or legal guardian) gives written informed consent for publication. Informed consent for this purpose requires that the patient be shown the manuscript to be published. When informed consent has been obtained it should be indicated in the manuscript.
In attempting to maintain patient anonymity, identifying details should be omitted where they are not essential. However, patient data should never be amended or falsified. Informed consent should be obtained whenever there is any doubt that anonymity can be assured.
Access Tokens
What is an access token?
An access token allows a single user to access a certain amount of content an indefinite number of times.
Most commonly, this is a single article - but can be any set of content, up to and including access to all of our content.
Why use an access token?
An access token offers a cost-effective and time-efficient way of offering access to a targeted group of people.
It allows an author to share their work with their colleagues, peers and friends effortlessly by providing them a link to directly access the article, increasing the visibility of the article and its readership.
Costs
Access tokens can be purchased in bundles of 50 at a time at a cost of £100 per 50 tokens. By comparison, a single pay-per-view article for a single user would cost US$60 for 24 hours of access. Therefore, an author can share his work at a cost of only £2 per person - with no expiry date!
How does it work?
An author should request access tokens directly through a staff member of Expert Reviews Ltd/Future Medicine Ltd/Future Science Ltd, stating the article which they wish to purchase the tokens for.
Once payment has been processed, the access tokens are immediately available for activation. The author will receive an automated e-mail that contains the details of how to share the access tokens with their colleagues, peers and friends - including an example 'blurb' which they can use as the base for any e-mail they might send.
Each user who wishes to access the content must be provided with the activation link (contained in the e-mail the author receives) - in order to access the content, they must simply click on the link, then register (or login, if already a registered user) and the content will be available to them.
There is no time limit within which the tokens must be activated, so there is no pressure on the author to ensure the content is accessed immediately.
Once all the access tokens have been used, additional bundles of 50 can be purchased and the author can continue to distribute his content in the same way as described above.
Open Access Option
Authors who wish to publish in any Future Medicine title can opt for our Open Access Option, allowing free access to the online version of their article.
Authors of accepted peer-reviewed articles may choose to pay a fee in order for their published article to be made freely accessible to all at www.future-medicine.com and flagged as such on the website.
For 2010, the Open Access Option fee is £1,700 (plus VAT, where applicable)
Authors are required to complete a license form and payment form. The publication fee is charged on acceptance of the article and payment in full should be paid within 30 days (preferably by credit card) by the author or other funding body. Authors not paying by credit card may request to be invoiced in US Dollars or Euros at the prevailing equivalent rate (using www.xe.com).
For articles submitted in 2010, authors whose institutions subscribe to the journal of publication are eligible to receive a 50% discount on Open Access Option fees.
Any additional standard publication charges (e.g. color images) will also apply.
All articles are subject to our standard peer-review process and will be accepted or rejected based on their own merit.
Wellcome Trust-funded authors can opt for our Open Access Option in order to comply with the Trust's policy for open access (see below).
If you have a query regarding our Open Access Option please contact Karen Rowland (Head of Production)
Self-archive policy
Our self-archiving policies are set out below. These differ according to the copyright status of the article. Authors should adopt the self-archiving policy corresponding to the publishing route that they have opted for. The first section sets out the policy applicable for instances where copyright is assigned to the publisher. The subsequent section explains the rights applicable where an author has chosen the open access option.
Where copyright is assigned to the publisher
This rights outlined here apply in circumstances where copyright has been assigned to the publisher.
i) Manuscripts that have been submitted for publication and entry into peer review
Once a manuscript has been submitted for publication and entered into peer review, authors may share print or electronic copies of an article with colleagues. In doing so, they should state that the article has been submitted for publication to [the specified journal]. The author(s) may also post an electronic version of an article on a personal website, the website of an employer or institution, or to free public servers.
ii) Post-acceptance
Once a manuscript has been accepted for publication, authors may share print or electronic copies of their version of an article with colleagues (not the final published version), use all or part of an article in other publications and use the article for educational or research purposes. Three months after publication, and subject to appropriate acknowledgment of the journal and full bibliographic reference for an article, authors may post their version of the article on a personal website. Twelve months after publication, and subject to appropriate acknowledgment of the journal and full bibliographic reference for an article, authors may post their version of the article on a personal website, their employer’s website or on free public servers in their subject area. Requests to post their version of the article on institutional or commercial websites, etc, within 12 months of publication should be directed to the publisher.
Requests for posting of the final published version on personal, institutional or commercial websites should be directed to the publisher.
Authors cannot reproduce an article for commercial purposes (i.e. for monetary gain on their own account or on that of a third party, or for indirect financial gain by a commercial entity). However, this does not affect an author’s rights to receive a royalty or other payment for works of scholarship.
Articles published via the open access option
The rights outlined below apply specifically to all articles published via the open access option route.
Provided that authors give appropriate acknowledgment to the journal and publisher, and cite the full bibliographic reference for the article when it is published, authors may share print or electronic copies of an article with colleagues, use all or part an article and abstract in personal compilations or other scholarly publications of their own work (and may receive a royalty or other payment for such work), use an article within their employer’s institution or company for educational or research purposes, including use in course packs.
Authors publishing via open access option route may post the final PDF of the article on their own personal website, on an employer’s website and on free public servers in their subject area. Electronic versions of an accepted article should include a link to the published version of the article together with the following: ‘For full bibliographic citation, please refer to the version available at www.futuremedicine.com’.
Third parties are entitled to use an article published via the open access option route, in whole or in part, in accordance with the conditions outlined in the Creative Commons Deed, Attribution 2.5 Non-Commercial (further details from www.creativecommons.org), which allows dissemination on an open access basis, but does not permit commercial exploitation or the creation of derivative works without permission. Please address any queries to permissions@futuremedicine.com.
National Institutes of Health public access policy
Effective April 7, 2008, the National Institutes of Health (NIH) has stated that it will “require that all investigators funded by the NIH submit, or have submitted for them to the National Library of Medicine’s PubMed Central an electronic version of their final peer-reviewed manuscripts upon acceptance for publication, to be made publicly available no later than 12 months after the official date of publication…”
To assist our NIH-supported authors in meeting these requirements, Future Medicine will post the accepted manuscript to PubMed Central on their behalf. Authors will be asked to indicate the funding source as part of the submission process and the identified manuscripts will be transmitted to PubMed Central. The Publisher will also submit a copy of the final PDF no later than 12 months after the official date of publication.
If you require further assistance or have any questions, please contact Karen Rowland, Head of Production.
Wellcome Trust open access policy compliance
In order to comply with Wellcome Trust policy for open access, Wellcome Trust-funded authors are able to opt for our Open Access Option, whereby in return for payment of an article processing fee and signing our Open Access agreement, we will make their article freely available to subscribers and nonsubscribers on our website, and arrange for the final published version to be deposited into PubMed Central and UK PubMed Central within 4 weeks of publication. Third parties will be entitled to re-use the Article, in whole or in part, in accordance with the conditions outlined in the Creative Commons Deed, Attribution 2.5 attribution, Non-Commercial, No Derivatives (CC-BY-NC-ND).
Editorial Board
Overseeing the editorial content and development of Future Oncology is an Editorial Advisory Board, composed of many of the world's leading experts within the area of drug research and development.
Allison R: Brody School of Medicine, USA
Ron Allison, MD, is the Chairman and Professor of Radiation Oncology at The Brody School of Medicine, where he is also the Clinical Director of Photodynamic Therapy. He received his M.D. at SUNY-Downstate Medical School in Brooklyn, New York. Dr Allison served his residency training in Radiation Oncology at the State University in New York. Dr Allison has introduced state of the art therapy for cancer patients of Eastern N.C. This included the introduction of Image Guided Radiation Therapy and Intensity Modulated Radiation Therapy. He has been invited to lecture nationally and internationally on this subject. Further he is an authority on the oncologic use of Photodynamic Therapy.
Arlen P: National Institutes of Health, USA
Philip M. Arlen, M.D., is currently a Senior Clinical/Scientific Investigator in the Laboratory of Tumor Immunology and Biology, Center for Cancer Research, NCI, and is the Director of the Clinical Research Group. Dr Arlen is also a member of the senior medical staff at both the NCI Clinical Center and the National Naval Medical Center. He is both Principal and Co-Investigator on numerous clinical trials in prostate cancer, in addition to trials involving immunotherapy and other molecular target initiatives.
Berstein LM: Petrov Research Institute of Oncology, St. Petersburg, Russia
Lev M. Berstein is Chief of Laboratory of Oncoendocrinology at Petrov Research Institute of Oncology, St. Petersburg, Russia. His main scientific interests include mechanisms of hormonal carcinogenesis, studying of risk factors of hormone-associated tumors and new approaches to prevention and treatment of the latter. He received several international distinctions (including UICC Translational Cancer Research Fellowship), serves as a Member of Council of Russian Endocrine Association, at editorial boards of two national journals and as a reviewer for Future Oncology, J.Cancer Res.Clin.Oncol., Mol.Cell.Endocrinology, Cancer Epidemiology,Biomarkers & Prevention and oth. In his bibliography are 7 monographs, 16 chapters and more than hundred papers in peer-reviewed journals. He graduated as MD at Tartu University in Estonia and got his PhD and DMS degrees in Cancer Endocrinology at Petrov Institute in St.Petersburg.
Blagosklonny MV: New York Medical College, USA
Brandes AA: University Hospital, Padova, Italy
Cheng L: Indiana University School of Medicine, USA
Dr Liang Cheng is Associate Professor of Pathology and Laboratory Medicine and Urology, and the Director of Molecular Pathology Laboratory at the Indiana University School of Medicine (Indianapolis, IN, USA). He is board-certified in Clinical, Anatomic, and Molecular Genetic Pathology by the American Board of Pathology. He entered the medical program in Beijing Medical University, China at the age of 15. Dr Cheng completed his residency training at Case Western Reserve University and University Hospitals, Cleveland, OH, USA, and his fellowship training at the Mayo Clinic and Mayo Foundation, Rochester, MN, USA. Dr Cheng has received numerous prestigious awards, including the Stowell-Orbison Award from the United States and Canadian Academy of Pathology; and the Koss Medal Award for Eminent Services from the International Society of Urological Pathology. He was the 2006 Arthur Purdy Stout Prize Recipient from the Arthur Purdy Stout Society of Surgical Pathologists. Dr Cheng is a reviewer of more than 40 journals and a member of 12 Editorial Boards, and has published over 190 peer-reviewed scientific journal papers, in journals including Proceedings of the National Academy of Sciences, Journal of the National Cancer Institute, Nature Biotechnology, Journal of Clinical Oncology, American Journal of Pathology, Cancer Research, Oncogene and Clinical Cancer Research.
Correa P: Louisiana State University, USA
Costa N: Portuguese Instit. of Oncology, Portugal
Danesi R: University of Pisa, Italy
Dr. Danesi received his M.D. degree in 1983 from the University of Pisa, Italy, and his Ph.D. degree in Pharmacology of Cancer Chemotherapy from the Superior School S. Anna, Pisa, Italy in 1988. Since 2003 he is visiting professor in the Molecular Pharmacology Section, Cancer Therapeutics Branch, Center for Cancer Research, NCI, Bethesda, MD. Dr. Danesi is board certified in Diseases of the Lung (1988), Clinical Pharmacology (2001) and Medical Oncology (2006). He was appointed assistant professor of Pharmacology in 1991 at the Superior School S. Anna, Pisa; then he joined the Faculty of Medicine and Surgery of Pisa University in 1991, where he was associate professor of Chemotherapy from 1998 to 2005 and then full professor of Pharmacology since 2005. Dr Danesi is presently Chief of the Section of Cancer Pharmacology of Pisa University Hospital and Chair of the Ethics Committee of the same institution. Dr. Danesi’s main research interests are rational and accelerated development of new drugs for cancer therapy, pharmacogenetic approach to treatment optimization, gene expression and proteomics, development of new genetic markers for disease prognosis, prediction of response and toxicity of anticancer agents. He also has a longstanding interest in clinical pharmacology and pharmacodynamics of anticancer agents.
Since 1985, he published full papers in and is a reviewer for many prestigious international journals. Finally, he is member of the Grant Review Committee of the European Commission, Swiss Group for Clinical Cancer Research (SAKK), the Grant Agency of the Czěck Republic (GACR), the Italian National Research Council (CNR) and the Italian Ministry of Education, University and Research (MIUR).
de Vries E: Uni. Medical Center Groningen, The Netherlands
Di Carlo I, University of Catania, Italy
Dicker A: Thomas Jefferson University, USA
Dr Dicker is Professor of Radiation Oncology and Director of the Division of Experimental Radiation Oncology in the Department of Radiation Oncology at Thomas Jefferson University. He leads the Molecular Targets and Developmental Therapeutics Program at the Kimmel Cancer Center at Thomas Jefferson University Hospital and is responsible for Phase I trials with novels agents.
Dr Dicker graduated from Columbia College and received his MD and PhD from Cornell University Medical College. He completed an internship in Surgery at Lenox Hill Hospital and completed his residency in Department of Radiation Oncology at the Memorial Sloan-Kettering Cancer Center.
His laboratory research, funded by the National Cancer Institute, involves studying the role of the epidermal growth factor receptor (EGFR) and tumor microenvironment in solid tumors. His research evaluates radiosensitization by EGFR blockade through an understanding of survival signals derived from extracellular matrix (ECM). His recent work studies deregulated NF-kB signaling and its role in cancer biology. Dr Dicker’s other research effort builds on the use of zebrafish as a model organism to study molecular mechanisms of damage by radiation and chemotherapy. Dr Dicker’s laboratory program uses this model organism in conjunctional with nanotechnology drugs (nanoparticles) to identify novel radiation protectors/mitigators. In the field of prostate cancer, over the past decade, Dr Dicker and his colleagues have contributed a number of original papers in the field of prostate brachytherapy. These papers have focused on the definition and evaluation of post-implant dosimetry and its effect on the actual dose to the prostate, urethra and rectum. More recently, this group has focused on quality life issues after prostate brachytherapy and predictive factors that will help the guide the physician and individualize the appropriate therapy for treatment of prostate cancer for the respective patient. Dr Dicker and his colleagues have recently published a comprehensive text, “Basic and Advanced Techniques in Prostate Brachytherapy”, Frances & Taylor, 2005 that reviews in detail all aspects of prostate cancer and brachytherapy, with particular attention to practical techniques and issues that can be incorporated into daily practice.
Dr Dicker serves as the Vice Chair for Translational Research and Chair of the Translational Research Committee in the Radiation Therapy Oncology Group (RTOG) a National Cancer Institute sponsored cooperative group. In addition, he is the principal investigator on a number of “first in man” clinical developmental therapeutic protocols involving novel signal transduction agents at Thomas Jefferson University. Dr Dicker is Chair of the ASTRO Radiation Biology and Cancer Committee and also serves as a member of the Corporate Relations Committee. Dr Dicker is a board certified radiation oncologist. Among other honors, he has received an American Cancer Society Fellowship and an ASTRO/ESTRO Travel Grant.
Eberhardt W: University Hospital, Essen, Germany
Ellis I: University of Nottingham, UK
Fabbro D: Novartis Pharma AG, Switzerland
Febbo P: Duke University, USA
Gleave M: The Prostate Center at VA, Canada
Dr Gleave is a Distinguished Professor in the Department of Surgery at the University of British Columbia, Director of Clinical Research at the Prostate Center at Vancouver General Hospital, and Director of Research for the Division of Urology at UBC. He is a Senior Research Scientist at the Prostate Research Lab at Vancouver General Hospital and the GU Tumour Group Chair at BC Cancer Agency, and is appointed as a Consultant Urologist for the Department of Urology at the University of Washington. Dr. Gleave’s current research focuses on the study of cellular and molecular mechanisms that mediate progression of prostate cancer to its lethal stage of androgen independence, and on the use of this information to develop integrated multi-modality therapies that specifically target these mechanisms. He has published more than 150 peer-reviewed papers, and currently has more that $40M in peer reviewed funding. He is a recipient of many awards, including the NCIC's prestigious William Rawls Award for contributions to cancer control in Canada, Distinguished University Scholar designation by the University of British Columbia, and in 2005, was awarded the BC Leadership Chair in Prostate Cancer Research. He has characterized the functional role of many survival genes (bcl-2, clusterin, Hsp27, IGFBP-5, IGFBP-2) in cancer progression, leading to several patented targeted inhibitors, and first-in-man trials of new anti-cancer drugs. As Founder and CSO of OncoGenex, he is familiar with role of industry in translating preclinical observations into the clinic. He is active in clinical trials across Canada and is Chairman of the National Cancer Institute of Canada GU Clinical Trials Group, and Chairman of the Canadian Uro-Oncology Group.
Glimelius S: University Hospital Uppsala, Sweden
Godwin A: Fox Chase Cancer Center, USA
Harbeck N: Technical University Munich, Germany
Nadia Harbeck is an Associate Professor in the Department of Obstetrics and Gynaecology, Technical University of Munich, Munich, Germany, where she is responsible for breast cancer systemic therapy (including trials) and coordinating clinical breast cancer research. Professor Harbeck is a member of the expert panel issuing the yearly updated evidence-based AGO Guidelines for breast cancer therapy in Germany (www.ago-online.de). In addition, she is a steering committee member of the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology Group and the Breast Cancer Group of the Munich Tumor Center. Her translational research focuses on prognostic and predictive factors in breast cancer and other solid tumors as well as introduction of new targeted therapies into the clinic. Regarding the uPA/PAI-1 system, she is co-chair of the second multicenter clinical trial (NNBC-3) which uses these factors for clinical decision making in node-negative breast cancer. In addition, she is principal investigator or steering committee member of numerous other national and international clinical breast cancer trials, with a recent focus on trials using targeted compounds. Prof. Harbeck is a member of the international TransHERA as well as co-chair of TransALTTO committee. Professor Harbeck has authored more than 180 papers in peer-reviewed journals. For her clinical translational research, she has received numerous awards, including a 2001 AACR award, the 2001 ASCO Fellowship Merit Award and the 2002 AGO Schmidt-Matthiesen Award. In 2008, Prof. Harbeck gave the Emmanuel van der Schueren Lecture at the European Breast Cancer Conference (EBCC) 6 in Berlin.
Jassem J: Medical University of Gdansk, Poland
Jacek Jassem is Professor of Radiotherapy and Clinical Oncology, and since 1990 - Head of the Department of Oncology and Radiotherapy at the Medical University of Gdańsk, Poland. His main scientific interests include lung cancer, breast cancer, head and neck cancer, and molecular oncology. He is an author of over 300 research papers and scientific reviews in highly qualified peer reviewed scientific Polish and international journals. He is an author or co‑author of 25 oncology textbooks. He is a member of the editorial boards of 22 international and Polish medical journals. Between 1999 and 2002 he served as a member of the European Society for Therapeutic Radiology and Oncology Board, between 2000 and 2003 - as a chairman of the EORTC Breast Cancer Group and the EORTC General Assembly, and since 1999 is the chairman of the Central and East European Oncology Group. Since 2004 he is a member of the ASCO International Affairs Committee and since 2005 - a chairman-elect of the ASCO International Development and Education Award Program. Since 2002 he is a vice‑president of the Polish Oncological Society, since 1998 - a vice-president of the Polish Society of Radiation Oncology and since 2000 - a Member of the Scientific Council of the National Cancer Institute in Warsaw.
Kaufman H: Rush University Medical Center, USA
Lemoine N: Cancer Research UK Clinical Centre, UK
Mills GB: MD Anderson Center, USA
Mundle S: Rush University Medical Center, USA
Perez EA: Mayo Clinic, USA
Edith A. Perez, M.D. is the Deputy Director, Mayo Clinic Comprehensive Cancer Center for Florida, director of the Breast Program, and a professor of medicine at Mayo Medical School. She is a cancer specialist and an internationally known translational researcher at Mayo Clinic. Her roles extend nationally; including chairing the Breast Committee for the North Central Cancer Treatment Group, as well as other positions within the American Association for Cancer Research, the American Society of Clinical Oncology and the National Cancer Institute. Dr. Perez has developed and is involved in a wide range of clinical trials exploring the use of new therapeutic agents for the treatment and prevention of breast cancer. She also has developed studies to evaluate the role of genetic markers in the development and aggressiveness of breast cancer. Dr. Perez has authored more than 555 research articles in journals, books, and abstracts. Dr. Perez receives invitations to lecture at national and international meetings frequently. She serves on the editorial boards of multiple academic journals. Dr. Perez is a recipient of the Breast Cancer Research Foundation, Research Grant Award (1998-2010); the Horizon Achievement Award in Cancer Research (2002); the North Florida Hispanic of the Year Award (2003); the Mayo Clinic Outstanding Faculty Award (2002 & 2004); the Mayo Clinic Distinguished Educator Award (2003); the named Serene M. and Frances C. Durling Professorship of Medicine (2006); Honorary Doctorate of Letters, University of North Florida (2006); Mayo Clinic Distinguished Investigator (2007); the Florida State Biomedical Research Advisory Council [BRAC] (2009-2012) and member of Alpha Omega Alpha Honor Medical Society (2009).
Perng RP: National Yang-Ming University, Taiwan
Reichardt J: University of Sydney, Australia
Juergen Reichardt has a long and distinguished career in gene discovery and, more recently the functional assessment of DNA variants. Examples of these include: cloning of the gene for classic galactosaemia encoding galactose-1-phosphate uridyl transferase (GALT) with Nobel-prize winner Paul Berg in 1988. Reporting the first galactosaemia mutations with Savio Woo in 1992. Cloning the human gene for epimerase-deficiency galactosaemia (UDP-glucose 4’ epimerase; GALE) in 1995. Reporting the first association between genetic variants in the human steroid 5a-reductase type II (encoded by the SRD5A2 gene) and prostate cancer in 1999. He identified and characterized significant biochemical and pharmacogenetic variation in human steroid 5a-reductase type II (encoded by the SRD5A2 gene) in 2000. Discovering common somatic mutations in prostate cancer in the human steroid 5a-reductase type II (SRD5A2) gene in 2004.
He was on the faculty at USC (the University of Southern California) for 13 years. Professor Reichardt arrived in 2005 in Australia as the Plunkett Chair of Molecular Biology (Medicine) in Sydney where he expects to continue many of his investigations as well as to branch out into new areas by establishing new collaborations in Australia particularly in relationship to complex genetic traits for which there are gene-environment interactions involved in pathogenesis.
Rosell R: Catalan Institute of Oncology, Spain
Ross JS: Albany Medical College, USA
Jeffrey S. Ross, M.D. is a graduate of Oberlin College, Oberlin, Ohio and The State University of New York at Buffalo School of Medicine in Buffalo, New York. He served as an intern resident and fellow in Anatomic and Clinical Pathology at the Massachusetts General Hospital in Boston, Massachusetts. Dr Ross has received numerous academic awards, three patents in molecular diagnostics and is the author of more than 550 peer-reviewed scientific articles, research abstracts, 3 textbooks and numerous book chapters in the fields of pathology, molecular diagnostics, oncology and translational cancer research. Dr Ross serves as consultant for BioGenex, Inc., Millennium Pharmaceuticals, Inc., currently Veridex LLC, Centocor, LLC, speaker’s bureau and SAB for Genentech, Inc., President of Affiliated Pathology Services, PC and Chairman of the Department of Pathology and Laboratory Medicine at the Albany Medical College and Pathologist in Chief at the Albany Medical Center Hospital.
Scagliotti G: University of Torino, Italy
Dr Scagliotti is an Associate Professor of Respiratory Medicine in the Department of Clinical and Biological Sciences at the University of Torino in Torino, Italy. Prior to his current position, Dr Scagliotti was deputy head of the Respiratory Medicine Department at S. Luigi Gonzaga Hospital in Torino. He earned his medical degree and completed postgraduate training in respiratory medicine, internal medicine, and medical oncology at the University of Torino. Currently he is the Chief of the Thoracic Oncology Unit at the S. Luigi Hospital, Orbassano (Torino)
Dr Scagliotti’s research interests include experimental studies on basic and clinical applied research on lung cancer, including pharmacogenomic. He is the study coordinator of several European clinical trials on lung cancer therapy and he has been the chairman of the Biological Factors Subproject of the Adjuvant Lung Project Italy (BIOALPI).
Dr Scagliotti is a member of numerous scientific societies, including the Italian Society of Respiratory Medicine, the European Respiratory Society, the American Society of Clinical Oncology and American Association for Cancer Research. From 2002 to 2005 he was member of the International Affair Committee of the American Society of Clinical Oncology and currently he is Executive Board member of the International Association for the Study of Lung Cancer.
Dr Scagliotti is a reviewer for such journals as the European Respiratory Journal, Thorax, Lung Cancer, British Journal of Cancer, European Journal of Cancer, Annals of Oncology ,Lancet and Lancet Oncology, New England Journal of Medicine and Journal of National Cancer Institute. He currently serves on the editorial boards of Cancer Reports, Lung Cancer, Clinical Lung Cancer, Critical Review in Oncology and Hematology, and Oncology News. He is associate Editor for Journal of Thoracic Oncology. He is the author or co-author of more than 150 publications in peer-reviewed journals.
Schmoll HJ: Martin Luther University, Germany
Schwartz G: Comprehensive Cancer Center of Wake Forest University, USA
Shedden KA: University of Michigan, USA
Sikora K: Medical Solutions, UK
Karol Sikora is Professor of Cancer Medicine and honorary Consultant Oncologist at Imperial College School of Medicine, Hammersmith Hospital, London where he was Clinical Director of Cancer Services for 12 years. He is Scientific Director of Medical Solutions PLC, Britain’s leading cancer diagnostic company and Special Adviser to HCA International in the creation of the London Cancer Group - the largest UK cancer network outside the NHS in HCA’s six major London private hospitals. This includes the construction of a major new international cancer centre for care, teaching and research in London at the Harley St. Clinic with networked joint ventures with 5 major NHS Cancer Centres. He is Dean of the University of Buckingham’s new Medical School – Britain’s first independent school for over 200 years which expects its first intake in 2008.
Stebbing J: Imperial College of Medicine, UK
Dr Justin Stebbing (MD MRCP PhD), trained in medicine at Trinity College, Oxford, before undertaking a residency in internal medicine at the Johns Hopkins University Hospital, Batimore USA, followed by a fellowship in medical oncology at The Royal Marsden, London.
His sub-specialty interests included the management of individuals with breast and ovarian cancers, melanoma and AIDS-related malignancies.
He has been involved in a large number of phase I, II and III trials of novel and existing therapeutic compounds including the new targeted biologics such as anti-tumour monoclonal antibodies.
He was also a Medical Research Council funded Clinical Training Fellow and obtained his PhD from Imperial College, London on the interplay between the immune system, infection and cancer. This also focused on the development of immunotherapy to treat cancer.
He has published over 100 peer-reviewed papers, the majority as first author.
He was recently awarded first prize and a Bristol-Myers Squibb scholarship at the British HIV Association for his work on mechanisms of resistance to progressive infection and the role of the innate immune system in this process. Here, the immediate rejection of pathogens and/ or tumours was studied with attention to the cellular receptors involved. His collaborators in this work include Pramod Srivastava, Professor of Cancer Medicine and Director of Immunotherapy at the University of Connecticut, and Daniel Douek, Chief of Immunology at the NIH.
Tolcher AW: South Texas Accelerated Research Therapeutics, USA
Anthony W. Tolcher, M.D. is the Director of Clinical Research, and The John E. Freeman, M.D. Chair for Clinical Research, at The Institute for Drug Development, Cancer Therapy & Research Center. He is also a Clinical Professor of Medicine in the Division of Medical Oncology at The University of Texas Health Science Center at San Antonio.
Dr Tolcher’s major interest is in the development of new anticancer agents. He has an special interest in molecular genetic targets for cancer therapy.
He is a Fellow of the Royal College of Physicians of Canada; a Diplomate of the American Board of Internal Medicine and Medical Oncology; and a member of the Canadian Medical Association, the American College of Physicians, and the American Society of Clinical Oncologists. He also serves as a member of the American Society of Clinical Oncology Scientific Program Committee and the Cancer Education Committee.
Tonini G: University Campus Bio-Medico, Italy
Prof Giuseppe Tonini was born on August, 1956. He is professor of medical oncology and he is chief of the Division of Medical Oncology of the University Campus Bio-Medico in Rome. He is an active member of ASCO, ESMO and AIOM. He has been doing clinical research in the treatment of cancer and specifically lung and breast cancer for several years. To date, he has published about 100 full papers in international journals. Current fields of investigation: clinical and molecular aspects of solid cancer (gastrointestinal, lung and breast cancer), supportive care in cancer and angiogenesis
Van der Zee J: Daniel den Hoed Cancer Center, The Netherlands
Vansteenkiste J: Uni. Hosp. Gasthuisberg, Belgium
Professor Johan Vansteenkiste is Associate Professor of Internal Medicine in the Faculty of Medicine at the Catholic University of Leuven, Belgium, and Head of Clicic in the Respiratory Oncology and Clinical Trial Unit at the Leuven University Hospital.
Professor Vansteenkiste studied Medicine at the Catholic University of Leuven before becoming a Board Certified Pulmonologist-Oncologist. He had additional training in Respiratory Oncology at the European School of Oncology in Milan, Italy, and in Respiratory Endoscopy at the Laser Centre in Marseille, France, before gaining his PhD at the Catholic University of Leuven in 1996.
Professor Vansteenkiste is an active member of many different national and international societies devoted to lung cancer research. He was Secretary of the Thoracic Oncology Group of the European Respiratory Society from 1999-2003, member of its Thoracic Oncology Network from 2004 onwards, National Delegate for Belgium from 2003 till 2005, and currently Secretary of the ERS Clinical Assembly. He is the chairman of the Oncology Committee of the Belgian Society of Pneumology.
He is the principal investigator or co-investigator in several clinical trials in the area of lung cancer. He is Associate Editor at the Journal of Thoracic Oncology, and author or co-author of more than 100 papers and book chapters on Respiratory Oncology.
He is the recipient of several awards, including the ‘Eli-Lilly L. Hertel Chair in Respiratory Oncology’,and the ‘Amgen Fund in Supportive Cancer Care’, at the Catholic University of Leuven.
Workman P: Cancer Research UK Clinical Centre, UK
Zetter B: Harvard Medical School, USA
Dr Bruce Zetter is the Charles Nowiszewski Professor in the Departments of Cell Biology and Surgery at Harvard Medical School in Boston, MA. As the Chief Scientific Officer at Children’s Hospital Boston, Dr Zetter coordinates the research efforts and strategy for the hospital. Dr Zetter is highly regarded nationally and internationally as a leader in the research of tumor progression, cancer diagnosis, cancer metastasis, and tumor angiogenesis. Prior to his work at Harvard, Dr Zetter received a B.A. degree in Anthropology from Brandeis University in Waltham, MA, and a Ph.D. from the University of Rhode Island in Kingston, RI. He completed fellowships at MIT in Cambridge, MA and at the Salk Institute in San Diego, CA. Subsequently, he was an Assistant Research Biochemist at the University of California in San Francisco, California. Dr Zetter joined the faculty of Harvard Medical School in 1978 where he has directed the Physiology course for all first year medical students. For the past 20 years, Dr Zetter has conducted research at Children’s Hospital in Boston. His current research interests are focused on tumor metastasis and on the development of diagnostic and prognostic markers that can direct treatment decisions by physicians and patients.
Dr Zetter has won numerous national and international awards for his work in the field of cancer research including a Faculty Research Award from the American Cancer Society and the prestigious MERIT award from the US National Cancer Institute. He is also on the editorial board of eight peer-reviewed journals. He has chaired several research conferences including the Gordon Conference on Cancer considered one of America's premier cancer conferences. A frequent lecturer, he has given over 100 lectures to universities, conferences and businesses in the past ten years and recently served as an expert witness for the United States Senate Cancer Coalition hearings in Washington, DC. He has also received three teaching awards from the students at Harvard Medical School for excellence as a teacher and as a course director.
Dr Zetter also serves on several grant review boards for public agencies such as the American Heart Association and American Cancer Society. He chairs the National Institutes of Health review board on tumor progression and metastasis, has chaired review panels on breast and prostate cancer for NIH as well as for the U.S. Department of Defense and has chaired the NASA committee that selects scientific projects for the space shuttle. He also serves as a consultant and scientific advisor to major biotechnology and pharmaceutical companies.
| 
